Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors.
作者： Liang-Yu Lin , Yi-Chen Yeh , Chia-Huei Chu , Justin G.S. Won , Yi-Ming Shyr
DOI: 10.1097/MD.0000000000008262
关键词: Lung cancer 、 Tumor progression 、 Medicine 、 Internal medicine 、 Oncology 、 Progression-free survival 、 Cancer 、 Breast cancer 、 Neuroendocrine tumors 、 Hazard ratio 、 Proportional hazards model
摘要: Endocan expression has been reported to be associated with aggressive tumor progression and poor outcomes in various cancers, such as breast cancer, renal cell lung gastric pituitary adenomas. However, the prognostic significance of endocan neuroendocrine tumors remains unknown. Thus, aim this study was determine correlation between pancreatic (PNET) tissues progression-free survival. This included 73 patients confirmed PNETs who were treated a single tertiary center north Taiwan 1992 2015. Immunohistochemical microvessel density (MVD) examined, relationships these parameters other clinicopathological characteristics analyzed. The abovementioned divided into groups according their levels (≥1% or <1%) median MVDs. Negative (P = .002) high MVD (P < .001) significant favorable factors for positive significantly low (P = .037) mitosis (Ki-67 index) (P = .028). Multivariate Cox regression analysis showed that (hazard ratio: 4.778, P = .018) lymph node involvement 5.121, P = .005) independent recurrence.In conclusion, correlated clinical PNETs. Our data indicated may reliable marker predicting recurrence
sci-hub.se 参考文章(28)
Ta-Chiang Liu, Nicholas Hamilton, William Hawkins, Feng Gao, Dengfeng Cao, Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors. The American Journal of Surgical Pathology. ,vol. 37, pp. 853- 859 ,(2013) , 10.1097/PAS.0B013E31827FCC18
S. Sarrazin, E. Adam, M. Lyon, F. Depontieu, V. Motte, C. Landolfi, H. Lortat-Jacob, D. Bechard, P. Lassalle, M. Delehedde, Endocan or endothelial cell specific molecule-1 (ESM-1) : A potential novel endothelial cell marker and a new target for cancer therapy Biochimica et Biophysica Acta. ,vol. 1765, pp. 25- 37 ,(2006) , 10.1016/J.BBCAN.2005.08.004
Bogdan Dragos Grigoriu, Florence Depontieu, Arnaud Scherpereel, Delphine Gourcerol, Patrick Devos, Taoufik Ouatas, Jean-Jacques Lafitte, Marie-Christine Copin, Andre-Bernard Tonnel, Philippe Lassalle, , Endocan Expression and Relationship with Survival in Human Non–Small Cell Lung Cancer Clinical Cancer Research. ,vol. 12, pp. 4575- 4582 ,(2006) , 10.1158/1078-0432.CCR-06-0185
G. Rindi, M. Falconi, C. Klersy, L. Albarello, L. Boninsegna, M. W. Buchler, C. Capella, M. Caplin, A. Couvelard, C. Doglioni, G. Delle Fave, L. Fischer, G. Fusai, W. W. de Herder, H. Jann, P. Komminoth, R. R. de Krijger, S. La Rosa, T. V. Luong, U. Pape, A. Perren, P. Ruszniewski, A. Scarpa, A. Schmitt, E. Solcia, B. Wiedenmann, TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study Journal of the National Cancer Institute. ,vol. 104, pp. 764- 777 ,(2012) , 10.1093/JNCI/DJS208
Xavier Leroy, Sebastien Aubert, Laurent Zini, Helene Franquet, Gwenola Kervoaze, Arnauld Villers, Maryse Delehedde, Marie-Christine Copin, Philippe Lassalle, Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma Histopathology. ,vol. 56, pp. 180- 187 ,(2010) , 10.1111/J.1365-2559.2009.03458.X
James C. Yao, Manal Hassan, Alexandria Phan, Cecile Dagohoy, Colleen Leary, Jeannette E. Mares, Eddie K. Abdalla, Jason B. Fleming, Jean-Nicolas Vauthey, Asif Rashid, Douglas B. Evans, One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States Journal of Clinical Oncology. ,vol. 26, pp. 3063- 3072 ,(2008) , 10.1200/JCO.2007.15.4377
Eduardo Vilar, Ramon Salazar, Jose Perez-Garcia, Javier Cortes, Kjell Oberg, Josep Tabernero, None, Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors Endocrine-related Cancer. ,vol. 14, pp. 221- 232 ,(2007) , 10.1677/ERC-06-0074
Anne Tsicopoulos, André-Bernard Tonnel, Thibaut Gentina, Bogdan Grigoriu, Stéphanie Sénéchal, Anne Janin, Philippe Lassalle, François Plénat, David Béchard, Arnaud Scherpereel, Overexpression of Endocan Induces Tumor Formation Cancer Research. ,vol. 63, pp. 6084- 6089 ,(2003)
Guido Rindi, Cesare Bordi, Aetiology, molecular pathogenesis and genetics Best Practice & Research in Clinical Gastroenterology. ,vol. 19, pp. 519- 534 ,(2005) , 10.1016/J.BPG.2005.03.005
M Fraenkel, M Kim, A Faggiano, W W de Herder, G D Valk, _ _, Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature Endocrine-related Cancer. ,vol. 21, ,(2014) , 10.1530/ERC-13-0125